SUDA Signs Term Sheet To Acquire Anti-Cancer Agent
Filed with ASX · · 2 pages · English
Arovella Therapeutics Limited on 6ix
Earlier from Arovella Therapeutics
- SUDA Meeting For Zolpimist Into Europe
- Placement, Interest Shares and Convertible Note Prospectus
- SUDA Completes $1.5m Capital Raising
- SUDA Submits Application For ArTiMist
- SUDA Extends Maturity of Convertible Notes
Later from Arovella Therapeutics
- SUDA Enters Licence Agreement With Teva
- Strong Revenue Growth for SUDA Subsidiary
- SUDA Achieves ISO Accreditation
- SUDA Publishes Amended Shareholder Newsletter
- SUDA Acquires Novel Oro-Mucosal Anti-Cancer Agent
Follow Arovella Therapeutics into a list and get an email when it puts out news.
Follow Arovella Therapeutics